Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Novo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema, in patients with obesity and type 2 ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.

Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...

"Recall that CagriSema is more difficult to manufacture than tirzepatide due to its dual-chamber device, and NVO's future manufacturing capacity is TBD," wrote Leerink Partners analyst David ...